AU2012322991B2 - Treatment for rheumatoid arthritis - Google Patents

Treatment for rheumatoid arthritis Download PDF

Info

Publication number
AU2012322991B2
AU2012322991B2 AU2012322991A AU2012322991A AU2012322991B2 AU 2012322991 B2 AU2012322991 B2 AU 2012322991B2 AU 2012322991 A AU2012322991 A AU 2012322991A AU 2012322991 A AU2012322991 A AU 2012322991A AU 2012322991 B2 AU2012322991 B2 AU 2012322991B2
Authority
AU
Australia
Prior art keywords
ser
gly
val
thr
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012322991A
Other languages
English (en)
Other versions
AU2012322991A1 (en
Inventor
Alex GODWOOD
Fabio MAGRINI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of AU2012322991A1 publication Critical patent/AU2012322991A1/en
Priority to AU2018200560A priority Critical patent/AU2018200560A1/en
Application granted granted Critical
Publication of AU2012322991B2 publication Critical patent/AU2012322991B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012322991A 2011-10-10 2012-10-10 Treatment for rheumatoid arthritis Active AU2012322991B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018200560A AU2018200560A1 (en) 2011-10-10 2018-01-24 Treatment for rheumatoid arthritis

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161545359P 2011-10-10 2011-10-10
US61/545,359 2011-10-10
US201161556974P 2011-11-08 2011-11-08
US61/556,974 2011-11-08
PCT/EP2012/070074 WO2013053767A1 (en) 2011-10-10 2012-10-10 Treatment for rheumatoid arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018200560A Division AU2018200560A1 (en) 2011-10-10 2018-01-24 Treatment for rheumatoid arthritis

Publications (2)

Publication Number Publication Date
AU2012322991A1 AU2012322991A1 (en) 2014-03-27
AU2012322991B2 true AU2012322991B2 (en) 2018-02-15

Family

ID=47010599

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012322991A Active AU2012322991B2 (en) 2011-10-10 2012-10-10 Treatment for rheumatoid arthritis
AU2018200560A Abandoned AU2018200560A1 (en) 2011-10-10 2018-01-24 Treatment for rheumatoid arthritis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018200560A Abandoned AU2018200560A1 (en) 2011-10-10 2018-01-24 Treatment for rheumatoid arthritis

Country Status (9)

Country Link
US (1) US20140335081A1 (OSRAM)
EP (1) EP2766394B1 (OSRAM)
JP (1) JP6239517B2 (OSRAM)
CN (1) CN103906767A (OSRAM)
AU (2) AU2012322991B2 (OSRAM)
CA (1) CA2851322C (OSRAM)
ES (1) ES2660776T3 (OSRAM)
RU (1) RU2014117510A (OSRAM)
WO (1) WO2013053767A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105705518A (zh) * 2013-08-30 2016-06-22 塔科达有限责任公司 用于治疗类风湿性关节炎或作为镇痛药的中和gm-csf的抗体
JP2017515828A (ja) * 2014-05-19 2017-06-15 メディミューン リミテッド 関節リウマチのための治療
WO2017202879A1 (en) 2016-05-24 2017-11-30 Medimmune Limited Anti-pad4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis
WO2018144334A1 (en) * 2017-02-02 2018-08-09 Imclone Llc Dosing regimen for anti-csf-1r antibody
US11078264B2 (en) 2018-10-17 2021-08-03 University Of Connecticut Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth
WO2020096664A1 (en) 2018-11-09 2020-05-14 Kiniksa Pharmaceuticals, Ltd. Treatment for giant cell arteritis
BR112021008688A2 (pt) 2018-11-09 2021-08-10 Kiniksa Pharmaceuticals, Ltd. tratamento para arterite de célula gigante
WO2020239090A1 (zh) * 2019-05-31 2020-12-03 广州市雷德生物科技有限公司 一种类风湿关节炎相关的特异性多肽及其应用
JP2022535062A (ja) 2019-06-03 2022-08-04 キニクサ ファーマシューティカルズ, リミテッド Gm-csf拮抗薬を用いたがんの治療
US20210284744A1 (en) 2020-03-15 2021-09-16 Kiniksa Pharmaceuticals, Ltd. Treatment of cytokine release syndrome with gm-csf antagonists
WO2022093855A1 (en) 2020-10-26 2022-05-05 Kiniksa Pharmaceuticals, Ltd. Treatment of cancers with gm-csf antagonists
WO2025218746A1 (en) * 2024-04-17 2025-10-23 Sinomab Bioscience Limited Methods of treating rheumatoid arthritis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007110631A1 (en) * 2006-03-27 2007-10-04 Medimmune Limited Binding member for gm-csf receptor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US565332A (en) 1896-08-04 Toy for making soap-bubbles
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
DE69941267D1 (de) 1998-12-10 2009-09-24 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
US6881557B2 (en) 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
MXPA04005080A (es) * 2004-05-27 2005-11-30 Aspid S A De C V Una composicion moduladora de la inflamacion articular cronica a base de colagena-polivinilpirrolidona.
DK2049123T4 (en) * 2006-08-03 2016-11-28 Horizon Pharma Ag LATE discharge-glucocorticoid treatment of rheumatoid ILLNESS
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
EP2531613A2 (en) * 2010-02-02 2012-12-12 Abbott Biotechnology Ltd. Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007110631A1 (en) * 2006-03-27 2007-10-04 Medimmune Limited Binding member for gm-csf receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BURMESTER, GR et al; ANNALS OF THE RHEUMATIC DISEASES, vol. 70, no. 9, 1 September 2011 (2011-09-01 ), pages 1542-1549 *

Also Published As

Publication number Publication date
AU2012322991A1 (en) 2014-03-27
EP2766394B1 (en) 2017-11-22
US20140335081A1 (en) 2014-11-13
JP2014534956A (ja) 2014-12-25
WO2013053767A1 (en) 2013-04-18
RU2014117510A (ru) 2015-11-20
AU2018200560A1 (en) 2018-02-15
JP6239517B2 (ja) 2017-11-29
ES2660776T3 (es) 2018-03-26
CA2851322A1 (en) 2013-04-18
HK1200855A1 (en) 2015-08-14
CN103906767A (zh) 2014-07-02
CA2851322C (en) 2020-03-31
EP2766394A1 (en) 2014-08-20

Similar Documents

Publication Publication Date Title
AU2012322991B2 (en) Treatment for rheumatoid arthritis
US20240124596A1 (en) Antibody molecule for human gm-csf receptor alpha
CN101711256B (zh) 针对il-25的抗体
BG106027A (bg) Човешки антитела, които свързват човешки il-12 и методи за получаване
US20160272706A1 (en) Il-13 binding proteins and uses thereof
WO2019148405A1 (zh) IL-4Rα抗体及其用途
HK1200855B (en) Treatment for rheumatoid arthritis
AU2007231128B2 (en) Binding member for GM-CSF receptor
AU2013200962A1 (en) Binding member for GM-CSF receptor
HK1166989B (en) Binding member for gm-csf receptor
HK1166988B (en) Binding member for gm-csf receptor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)